NRX Pharmaceuticals (NRXP) Cash from Investing Activities (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Cash from Investing Activities of -$213000.0 for Q1 2026, up 14.46% quarter-over-quarter from -$249000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Cash from Investing Activities (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Cash from Investing Activities for 9 consecutive years, with -$213000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$213000.0; the TTM figure through Mar 2026 stood at -$462000.0 (changed N/A YoY), while the FY2025 annual figure was -$2.8 million, changed N/A from the prior year.
- Cash from Investing Activities advanced to -$213000.0 in Q1 2026 per NRXP's latest filing, from -$249000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $2000.0 in Q2 2023 and bottomed at -$249000.0 in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$47500.0 across 4 years, with a median of -$3000.0 in 2022.
- On a YoY basis, Cash from Investing Activities climbed as much as 166.67% in 2023 and fell as far as 33.33% in 2023.
- NRX Pharmaceuticals' Cash from Investing Activities stood at $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then slumped by 25000.0% to -$249000.0 in 2025, then gained by 14.46% to -$213000.0 in 2026.
- Business Quant data shows NRXP's Cash from Investing Activities at -$213000.0 in Q1 2026, -$249000.0 in Q4 2025, and $1000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -684,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -213,000.00 |
| Mar 31, 2026 | -213,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Dec 31, 2025 | -249,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -5,000.00 |
| Sep 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Mar 31, 2022 | -3,000.00 |